Owl Creek Asset Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-267,189
Closed -$8.02K 204
2022
Q4
$8.02K Sell
267,189
-107,644
-29% -$4.73K ﹤0.01% 193
2022
Q3
$22K Hold
374,833
﹤0.01% 221
2022
Q2
$34K Hold
374,833
﹤0.01% 249
2022
Q1
$97K Hold
374,833
﹤0.01% 263
2021
Q4
$551K Sell
374,833
-297,224
-44% -$414K 0.04% 187
2021
Q3
$995K Hold
672,057
0.04% 146
2021
Q2
$773K Hold
672,057
0.04% 156
2021
Q1
$551K Hold
672,057
0.02% 159
2020
Q4
$974K Sell
672,057
-8,443
-1% -$10.6K 0.04% 79
2020
Q3
$803K Hold
680,500
0.05% 62
2020
Q2
$681K Hold
680,500
0.05% 52
2020
Q1
$442K Buy
+680,500
New +$535K 0.04% 56

Other funds holding JSPRW

Owl Creek Asset Management's JSPRW Position: Q1 2023 in Review

Owl Creek Asset Management sold out of Japer Therapeutics Warrants (JSPRW) in Q1 2023, closing a stake of 267,189 shares — an estimated $8.02K sold.

Owl Creek Asset Management first reported a position in JSPRW in Q1 2020 and held it in 12 quarters. The position peaked at $995K in Q3 2021. 10 funds tracked by Wall St. Rank hold JSPRW as of Q1 2023.

  • Owl Creek Asset Management reported no remaining Japer Therapeutics Warrants position as of Q1 2023 after selling out during the quarter.
  • Owl Creek Asset Management sold 267,189 Japer Therapeutics Warrants shares in Q1 2023, an estimated $8.02K.
  • Owl Creek Asset Management first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 12 quarters.
  • Owl Creek Asset Management's Japer Therapeutics Warrants position peaked at $995K in Q3 2021.
  • 10 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q1 2023.

Based on Owl Creek Asset Management's 13F filing for Q1 2023, filed 15 May 2023.